Haleon (HLN) Revenue & Revenue Breakdown
Haleon Revenue Highlights
Latest Revenue (Y)
$11.30B
Latest Revenue (Q)
$2.92B
Main Segment (Y)
Respiratory Health
Main Geography (Y)
Rest of World
Haleon Revenue by Period
Haleon Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $11.30B | 4.09% |
| 2022-12-31 | $10.86B | 13.76% |
| 2021-12-31 | $9.54B | -3.51% |
| 2020-12-31 | $9.89B | 16.65% |
| 2019-12-31 | $8.48B | - |
Haleon generated $11.30B in revenue during NA 2023, up 4.09% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Haleon Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $2.92B | 5.53% |
| 2023-12-31 | $2.77B | -1.14% |
| 2023-09-30 | $2.80B | 1.67% |
| 2023-06-30 | $2.75B | -7.84% |
| 2023-03-31 | $2.99B | -21.28% |
| 2022-12-31 | $3.79B | 31.15% |
| 2022-09-30 | $2.89B | 12.92% |
| 2022-06-30 | $2.56B | -2.51% |
| 2022-03-31 | $2.63B | 79.32% |
| 2021-12-31 | $1.47B | -41.16% |
| 2021-09-30 | $2.49B | - |
Haleon generated $2.92B in revenue during Q1 2024, up 5.53% compared to the previous quarter, and up 76.96% compared to the same period a year ago.
Haleon Revenue Breakdown
Haleon Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 |
|---|---|
| Respiratory Health | $1.58B |
Haleon's latest annual revenue breakdown by segment (product or service), as of Dec 22: Respiratory Health (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 23 |
|---|---|
| Respiratory Health | $839.00M |
Haleon's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Respiratory Health (100.00%).
Haleon Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 |
|---|---|
| CHINA | $907.00M |
| Rest of World | $5.91B |
| UNITED STATES | $3.69B |
Haleon's latest annual revenue breakdown by geography, as of Dec 22: Rest of World (56.24%), UNITED STATES (35.13%), and CHINA (8.63%).
Haleon Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company | $4.26T | $1.05T |
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| TEVA | Teva Pharmaceutical Industries | $15.85B | $4.16B |
| VTRS | Viatris | $15.43B | $3.66B |
| HLN | Haleon | $11.30B | $2.92B |
| BHC | Bausch Health Companies | $8.76B | $2.40B |
| ZTS | Zoetis | $8.54B | $2.36B |
| ELAN | Elanco Animal Health | $4.42B | $1.21B |
| CTLT | Catalent | $4.38B | $1.07B |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| LNTH | Lantheus | $1.30B | $394.09M |
| EBS | Emergent BioSolutions | $1.05B | $254.70M |
| HCM | HUTCHMED (China) | $838.00M | $152.56M |
| SIGA | SIGA | $139.92M | $21.81M |
| ESPR | Esperion Therapeutics | $116.33M | $73.83M |
| PETQ | PetIQ | $1.10M | $328.94M |
HLN Revenue FAQ
What is Haleon’s yearly revenue?
Haleon's yearly revenue for 2023 was $11.3B, representing an increase of 4.09% compared to 2022. The company's yearly revenue for 2022 was $10.86B, representing an increase of 13.76% compared to 2021. HLN's yearly revenue for 2021 was $9.54B, representing a decrease of -3.51% compared to 2020.
What is Haleon’s quarterly revenue?
Haleon's quarterly revenue for Q1 2024 was $2.92B, a 5.53% increase from the previous quarter (Q4 2023), and a -2.24% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.77B, a -1.14% decrease from the previous quarter (Q3 2023), and a -27.08% decrease year-over-year (Q4 2022). HLN's quarterly revenue for Q3 2023 was $2.8B, a 1.67% increase from the previous quarter (Q2 2023), and a -3.25% decrease year-over-year (Q3 2022).
What is Haleon’s revenue growth rate?
Haleon's revenue growth rate for the last 3 years (2021-2023) was 18.41%, and for the last 5 years (2019-2023) was 33.28%.
What are Haleon’s revenue streams?
Haleon's revenue streams in c 22 are Respiratory Health
What is Haleon’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Haleon was Respiratory Health. This segment made a revenue of $1.58B, representing 100.00% of the company's total revenue.